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USP11 regulates PML stability to control
Notch-induced malignancy in brain tumours
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Ya-Wen Lin1,4, Hsin-I. Ma1,5, Pang-Hsien Tu6, Sean E. Lawler7 & Ruey-Hwa Chen1,2,3
The promyelocytic leukaemia (PML) protein controls multiple tumour suppressive functions
and is downregulated in diverse types of human cancers through incompletely characterized
post-translational mechanisms. Here we identify USP11 as a PML regulator by RNAi
screening. USP11 deubiquitinates and stabilizes PML, thereby counteracting the functions of
PML ubiquitin ligases RNF4 and the KLHL20–Cul3 (Cullin 3)–Roc1 complex. We ﬁnd that
USP11 is transcriptionally repressed through a Notch/Hey1-dependent mechanism, leading to
PML destabilization. In human glioma, Hey1 upregulation correlates with USP11 and PML
downregulation and with high-grade malignancy. The Notch/Hey1-induced downregulation of
USP11 and PML not only confers multiple malignant characteristics of aggressive glioma,
including proliferation, invasiveness and tumour growth in an orthotopic mouse model, but
also potentiates self-renewal, tumour-forming capacity and therapeutic resistance of patient-
derived glioma-initiating cells. Our study uncovers a PML degradation mechanism through
Notch/Hey1-induced repression of the PML deubiquitinase USP11 and suggests an important
role for this pathway in brain tumour pathogenesis.
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T
he promyelocytic leukaemia (PML) tumour suppressor
gene was identiﬁed as a target for translocation with
retinoic acid receptor-a in acute PML1,2. The PML protein
is an essential component of discrete subnuclear structures called
PML nuclear bodies (PML-NBs)3, and is a regulator of multiple
cellular processes that are altered in cancer, such as proliferation,
senescence, cell death and migration4–6. PML-knockout mice
exhibit enhanced susceptibility to tumorigenesis when challenged
with carcinogens7 or in the context of additional oncogenic
events8,9. In accordance with its tumour suppressive functions,
PML protein downregulation is frequently observed in various
types of human cancer, including brain tumours10. Evidence has
emerged that ubiquitin-mediated proteasomal degradation is a
key mechanism leading to PML downregulation in tumours11.
For instance, a CK2-dependent and an E6AP-mediated PML
ubiquitination pathway are deregulated in non-small cell
lung cancer and Burkitt’s lymphoma, respectively8,12–14.
Recently, we identiﬁed a Roc1–Cul3–KLHL20-mediated PML
ubiquitination/degradation pathway, which participates in a
feedback mechanism to amplify HIF-1 signalling and tumour
hypoxia responses. Hyperactivation of this PML degradation
pathway is evident in prostate cancer and correlates with disease
progression15. Despite these ﬁndings, it remains undetermined
whether PML deubiquitination is abnormally regulated in
tumours, as this deubiquitination mechanism has not been
identiﬁed.
In addition to its tumour suppressive functions, PML plays
crucial roles in the maintenance and fate determination of
stem/progenitor cells. PML loss potentiates proliferation of
haematopoietic stem cells (HSCs)16 and impairs their asym-
metric division17, leading to HSC exhaustion. PML depletion in
mammary progenitor cells increases their proliferation and
disturbs the balance of two progenitor populations18. During
brain neocortical development, PML loss similarly increases the
proliferation of neural progenitor cells (NPCs) and compromises
their differentiation, thereby skewing the composition of NPC
subpopulations19. It remains undetermined whether PML exerts
similar function in the stem-like cell population of brain tumours
and whether PML itself is regulated by core pathways that drive
stemness programmes.
Glioma is the most common type of primary brain tumour,
and glioblastoma multiforme (GBM), a grade IV glioma, is the
most common and aggressive glial brain tumour20,21. The median
survival in GBM is 14.6 months with the current standard
treatment22. Emerging evidence indicates the existence of a
subpopulation of tumour cells in glioma with stem cell-like
characteristics, referred as glioma-initiating cells (GICs)23. GICs
exhibit sustained self-renewal and drive tumour initiation,
propagation and radio/chemoresistance24–28. Understanding
the mechanisms that govern GIC characteristics is therefore
critical to improve therapy for GBM as well as other aggressive
cancer types.
Notch signalling not only promotes GBM tumour cell
proliferation and invasion, but also has a crucial role in
maintaining GIC characteristics and supporting GIC niche
function29–33. In this study, we uncover a molecular
mechanism linking Notch signalling to PML degradation. We
show that Notch acts through Hey1 to repress the expression of
USP11, a deubiquitinating (DUB) enzyme for PML. This pathway
leads to PML destabilization and is deregulated in GBM.
We provide evidence indicating that this pathway promotes
multiple malignant features of GBM and GICs. Thus, our
study identiﬁes a PML degradation pathway mediated by
Notch-induced downregulaton of PML deubiquitinase USP11
and reveals the importance of this pathway in promoting GBM
malignancy.
Results
USP11 interacts with and stabilizes PML. To identify PML-
speciﬁc DUB, we carried out an unbiased loss-of-function screen
using short hairpin RNAs (shRNAs) to individually inhibit the
expression of 82 DUBs. HeLa cells transduced with lentivirus
carrying these shRNAs were analysed for PML immuno-
ﬂuorescence (Fig. 1a). DUBs with two or more shRNAs dis-
playing signiﬁcant reductions in both PML immunoﬂuorescence
and PML-NB number from two independent screens were USP11
and USP40 (Supplementary Fig. 1a). They were veriﬁed by a
secondary screen for the downregulation of PML protein. While
USP40 shRNAs did not affect PML expression (Supplementary
Fig. 1b), knockdown of USP11 by three independent shRNAs
induced downregulation of PML protein but not PML messenger
RNA (Fig. 1b). This downregulation was blocked by proteasome
inhibitor MG132 and was accompanied with a decrease of PML
protein half-life (Fig. 1c,d). Conversely, overexpression of USP11,
but not its catalytically dead mutant, elevated PML expression
(Fig. 1e). USP11 also increased PML half-life (Fig. 1f). These data
indicate that USP11 upregulates PML by preventing its protea-
somal degradation.
As USP11 knockdown did not affect the levels of RNF4 and
KLHL20 (Fig. 1b), two ubiquitin ligases for PML15,34,35, we
determined whether USP11 acts directly on PML. Coimmuno-
precipitation analysis revealed that USP11 interacted with both
PML-I and PML-IV in transfected cells (Fig. 1g). Interaction
between endogenous USP11 and endogenous PML was also
detected by reciprocal coimmunoprecipitations and the speciﬁcity
of this interaction was conﬁrmed by using lysates derived from
PML-null mouse embryonic ﬁbroblasts (MEFs; Fig. 1h).
Furthermore, puriﬁed USP11 and PML-I interacted in vitro
(Fig. 1i). Domain-mapping analysis revealed that USP11 bound
PML through its USP domain (Fig. 1j). Within the USP domain,
the carboxy-terminal segment encompassing residues 536–921
was responsible for PML interaction. These data support a direct
role of USP11 in regulating PML.
USP11 deubiquitinates PML. We next assessed the effect of
USP11 on PML ubiquitination. USP11 knockdown increased the
amount of PML-I modiﬁed by haemagglutinin (HA)-ubiquitin
(Fig. 2a). A similar result was obtained with another PML iso-
form, PML-IV (Fig. 2b). Puriﬁcation of ubiquitinated proteins
under denaturing conditions followed by western blot analysis of
PML further demonstrated the elevation of polyubiquitin mod-
iﬁcation on endogenous PML in USP11-knockdown cells
(Fig. 2c). In the reciprocal experiment, overexpression of USP11,
but not its catalytically inactive mutant, reduced PML ubiquiti-
nation (Fig. 2d). Next, we determined whether USP11 could
deubiquitinate PML in vitro. To this end, recombinant PML-I
was ﬁrst subjected to an in vitro ubiquitination assay in the
presence of E1, E2 and baculovirally puriﬁed Roc1–Cul3–
KLHL20 E3 ligase complex, and the resulting product was
incubated with baculovirally puriﬁed USP11 or its catalytically
dead mutant. We found that the polyubiquitin chain on
PML generated by in vitro ubiquitination was efﬁciently
removed by USP11, but not its mutant (Fig. 2e). These ﬁndings
collectively support that PML is a direct and physiological sub-
strate of USP11.
USP11 opposes the effects of PML ubiquitin ligases. PML
ubiquitination can be catalysed by RNF4 or the Roc1–Cul3–
KLHL20 complex. While the former speciﬁcally targets sumoy-
lated PML34,35, the latter does not distinguish sumoylated from
unmodiﬁed PML15. Remarkably, USP11 was able to antagonize
RNF4- and Roc1–Cul3–KLHL20-mediated PML ubiquitination
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in 293T cells and GBM cell line U87 (Supplementary Fig. 2a,b).
Consistent with a role in counteracting the function of
RNF4, USP11 prevented the degradation of sumoylated PML in
As2O3-treated cells (Supplementary Fig. 2c). However, since
USP11 was also capable of targeting PML ubiquitinated
by KLHL20-containing E3 ligase, its function was not restricted
to sumoylated PML and could efﬁciently deubiquitinate
a sumoylation-defective mutant of PML, PML-I-3KR34
(Supplementary Fig. 2d). Furthermore, under normal growth
conditions, USP11 upregulated both sumoylated and unmodiﬁed
PML (Supplementary Fig. 2e). Our results collectively indicate
that USP11 possesses a broad speciﬁcity to catalyse PML modiﬁed
by RNF4 or the Roc1–Cul3–KLHL20 complex.
USP11-mediated PML stabilization blocks GBM malignant
traits. Next, we investigated whether USP11-mediated PML
deubiquitination is impaired in certain tumours to result in PML
degradation. Analysis of the Genevestigator database revealed
that USP11 mRNA was abundantly expressed in the brain of
normal human tissues (Supplementary Fig. 3a). By searching the
Repository for Molecular Brain Neoplasia Data (REMBRANDT)
database, which contains microarray-derived gene expression
data from patients with malignant glioma, we found that USP11
mRNA was downregulated in glioma relative to non-tumour
brain tissues, with the grade IV GBM showing the highest extent
of downregulation (Supplementary Fig. 3b). We therefore asses-
sed the inﬂuence of USP11-dependent PML stabilization on the
hallmarks of GBM. For this purpose, we infected GBM cell line
U251 with lentivirus carrying USP11. This overexpression of
USP11 increased PML levels (Fig. 3a) and decreased several GBM
malignant traits, such as cell proliferation, migration and invasion
(Fig. 3b). To demonstrate that these tumour-suppressing func-
tions of USP11 resulted from PML upregulation, the USP11-
overexpressing cells were infected with lentivirus carrying PML
shRNA to reduce PML expression to a level comparable to that in
Lentivirus-based shRNA library
containing 403 shRNAs for 82 DUBs
Transduction of HeLa cells
Immunofluorescent staining
(anti-PML antibody, DAPI)
Automated image analysis of PML-NB signals by
cellomics ArrayScan VTI HCS reader 
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Figure 1 | USP11 interacts with and stabilizes PML. (a) Schematic presentation of the screening procedure to identify DUBs that regulate PML.
Representative images of cells transduced with lentivirus containing control or USP11 shRNA are shown on the bottom. Scale bar, 20mm. (b) USP11 shRNAs
reduce PML protein but not mRNA. HeLa cells transduced with lentivirus carrying USP11 shRNA or control shRNA were analysed by western blot with
indicated antibodies (top) or by reverse transcriptase–quantitative PCR (bottom). Data shown are mean±s.d. of three independent experiments. (c) HeLa
cells transduced with indicated lentiviruses were treated with 1 mM MG132 for 18 h and analysed by western blot. (d,f) The effects of USP11 knockdown (d)
or overexpression (f) on PML half-life. HeLa cells stably expressing indicated shRNAs (d), or U87 cells transfected with indicated constructs (f) were
treated with 100mgml 1 cycloheximide for indicated time periods and were analysed by western blot. The levels of PML relative to that seen at 0 h were
quantiﬁed and plotted on the left panels and the PML half-life in each cell is indicated on the bottom. (e) Western blot analysis of PML level in HeLa cells
transfected with indicated constructs. (g) USP11 interacts with PML-I and PML-IV. Coimmunoprecipitation analysis of 293Tcells transfected with indicated
constructs. (h) Interaction of endogenous PML with endogenous USP11 in T98G GBM cells and H4 glioma cells was analysed by coimmunoprecipitation.
Lysate of PML-null MEFs was used as a control. (i) USP11 and PML interact in vitro. Baculovirally puriﬁed USP11 bound on Myc-agarose beads was used to
pull down baculovirally puriﬁed PML-I. Bound proteins were analysed by western blot with indicated antibodies. (j) Mapping of the USP11 domain involved
in PML interaction. The domain organization of USP11 is shown on the top panel. Interaction of PML-I with indicated USP11 mutants in transfected 293T
cells was analysed by coimmunoprecipitation (bottom panels).
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control cells (Fig. 3a). Remarkably, this PML knockdown com-
pletely abrogated these tumour-suppressing effects of USP11
(Fig. 3b). In the reciprocal experiment, USP11 depletion in a low-
grade glioma cell line H4 not only reduced PML levels but also
promoted cell proliferation, migration and invasion (Fig. 3c,d).
Knockdown of PML phenocopied the effects of USP11 knock-
down. Furthermore, these tumour-promoting effects of USP11
shRNAs were completely blocked by expression of an shRNA-
resistant USP11, thus demonstrating the speciﬁcity of USP11
shRNA. More importantly, the effects of USP11 shRNAs were
also reversed by overexpression of PML-IV. Of note, PML-IV was
used in this experiment as it elicited stronger tumour suppressive
effects than PML-I (Supplementary Fig. 3c). Altogether, these
data indicate that USP11-dependent PML stabilization suppresses
multiple malignant traits of GBM.
Hey1 upregulation and USP11/PML downregulation in GBM.
Having demonstrated a tumour suppressive role of USP11 in
GBM, we next determined the aetiology of USP11 mRNA
downregulation in this type of cancer. To address whether USP11
is transcriptionally repressed in GBM, we utilized the PROMO
3.0 program to predict transcription factor-binding sites and
searched chromatin immunoprecipitation (ChIP)-seq databases
via the UCSC Genome Browser to uncover transcription factors
bound on the USP11 promoter. Among these candidates, we
focused on factors with transcriptional repression capabilities. We
then searched the REMBRANDT database to evaluate whether
these transcriptional repressors are upregulated in GBM and
whether their upregulation correlates with USP11 down-
regulation. Among transcription factors that satisﬁed these cri-
teria, we were particularly interested in Hey1 because it elicits an
opposite effect relative to PML on NPC maintenance19,36.
Furthermore, previous studies demonstrated that Hey1 is
upregulated in glioma and its overexpression correlates with
high-grade glioma and poor patient survival37,38. To validate the
clinical relevance of Hey1 in GBM and the correlation of its
expression with USP11 and PML expression, we performed
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Figure 2 | USP11 deubiquitinates PML and antagonizes the function of PML ubiquitin ligases. (a,b) USP11 shRNAs increase the ubiquitination
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immunohistochemistry (IHC) analysis on tissues derived from a
cohort of glioma patients. Representative IHC data from a grade
II specimen and a grade IV specimen were presented in Fig. 4a.
By analysing specimens from all patients, we found that grade IV
GBM exhibited signiﬁcant higher expression of Hey1 and
lower expression of USP11 and PML, in comparison with the
grade II/III patients (Fig. 4b). Furthermore, Hey1 expression
correlated inversely with USP11 and PML expression, whereas
USP11 expression correlated positively with PML expression
(Fig. 4c). These data strongly suggest the existence of a Hey1/
USP11/PML pathway in glioma and the association of its
hyperactivation with GBM.
Hey1 represses USP11 to downregulate PML. Next, we inves-
tigated whether Hey1 could regulate the expression of USP11 and
PML. Overexpression of Hey1 in GBM cell lines U87 decreased
USP11 mRNA and protein (Fig. 4d). Consistent with the reg-
ulation of PML protein stability by USP11, Hey1-induced USP11
downregulation resulted in a concomitant reduction of PML
protein but not mRNA. Similar results were obtained with
another GBM cell line, U251 (Fig. 4e). In the reciprocal experi-
ments, Hey1 knockdown in U87 and U251 cells upregulated
USP11 mRNA, USP11 protein and PML protein, but not PML
mRNA (Fig. 4f,g). Hey1 overexpression and knockdown also
decreased and increased the number of PML-NBs, respectively
(Supplementary Fig. 4a,b). These ﬁndings demonstrated a role of
Hey1 in downregulation of USP11 and PML.
Hey1 acts as a corepressor on the USP11 promoter. To explore
the mechanism of Hey1-induced USP11 downregulation, we
analysed the 50-regulatory region of USP11 (Fig. 5a). Using a set
of ChIP primers, we found that Flag-Hey1 bound to a region 30 to
the transcriptional start site of USP11 gene (Fig. 5b), which is
consistent with data retrieved from the ChIP-seq database.
Endogenous Hey1 also bound to this region and the binding was
not detected in Hey1-knockdown cells (Fig. 5c), thus demon-
strating the speciﬁcity of ChIP analysis. Using luciferase reporter
assay, we found that Hey1 repressed the USP11 promoter activity
and that the þ 171/þ 335 (0.16K) region of USP11 promoter was
responsible for this repression (Fig. 5d). Although this region
contains two E boxes, the preferred binding sites for Hey1, their
disruption did not affect Hey1-induced repression. Since an Sp1-
like factor was reported to cooperate with Hey1 in trans-
cription39, we investigated the role of several Sp1-binding sites
found in this region. Importantly, Hey1-induced repression of
USP11 was abrogated partially by mutating either of the ﬁrst two
Sp1 sites and completely by disrupting both (Fig. 5d), suggesting
that Hey1 acts through Sp1-binding sites to repress USP11.
Consistent with this notion, endogenous Sp1 was recruited to the
Hey1-binding region of USP11 promoter (Fig. 5e) and Sp1
depletion abolished Hey1 recruitment to this region (Fig. 5f).
Furthermore, re-ChIP analysis demonstrated the formation of
Sp1–Hey1 complex on the USP11 promoter (Fig. 5g). All of these
ﬁndings support a corepressor function of Hey1 in regulating
USP11 promoter activity. In contrast to this function of Hey1, Sp1
depletion did not signiﬁcantly alter USP11 promoter activity,
although it abrogated the effect of Hey1 short interfering RNA
(siRNA; Fig. 5h). These ﬁndings suggest a dual role of Sp1 in
regulating USP11 transcription and Hey1 binding switches the
function of Sp1 from an activator to a repressor (Fig. 5i).
We next investigated whether Hey1 recruitment alters chro-
matin structure to result in transcriptional repression. Remark-
ably, Hey1 depletion increased USP11 promoter-associated H3
130
130
100
55
100
70
PML shRNA #1 #2
Myc-USP11 –
– –
+
–
– –
+ + + + + + + + +
––
–
–
–
– –
– –
– –
– – –
– +
––
–
+ +
WB:PML
WB:Myc
WB:Tubulin
PML shRNA
Myc-USP11
0.0
0.5
1.0
1.5
*** *** *** *** *** ***
R
el
at
iv
e 
ac
tiv
iti
es
BrdU
incorporation
Migration Invasion
130
130
55
100
70
WB:PML
WB:USP11
WB:Tubulin
PML shRNA
Flag-USP11r
USP11 shRNA
#1 #2
#1 #3 #3
PML shRNA
Flag-USP11r
USP11 shRNA
0.0
0.5
1.0
1.5
2.0
2.5
0.5
1.0
1.5
2.0
2.5
3.0
0.0
0.5
1.0
1.5
2.0
Flag-PML-IV
#1 #3
R
el
at
iv
e 
ac
tiv
iti
es
***
***
*** *** ***
***
***
***
***
BrdU incorporation Migration Invasion
#1 #2 #1 #2 #1 #2
#1 #2
#1 #3 #3 #1 #3
#1 #2
#1 #3 #3 #1 #3
#1 #2
#1 #3 #3
kDa
kDa
0.0
–
–
–
– –
–
– –
–
– –
–
– –
–
– –
– – –
––
+ +
+
–
–
–
– –
–
– –
–
– –
–
– –
–
– –
– – –
––
+ +
+
–
–
–
– –
–
– –
–
– –
–
– –
–
– –
– – –
––
+ +
+
Figure 3 | USP11-mediated PML stabilization inhibits glioma cell migration and invasion. (a) Western blot analysis of USP11 and PML expression in U251
cells transduced with lentivirus carrying control ( ) or PML shRNA and/or USP11 expression construct. (b) Proliferation, migration and invasion
capabilities of U251 cells as in a. (c) Western blot analysis of USP11 and PML expression in H4 cells transduced with lentivirus carrying control ( ) or
indicated shRNAs and/or resistant USP11 (USP11r) construct. (d) H4 cells as in c were transduced with or without lentivirus carrying PML-IV and assayed
for proliferation, migration and invasion. Data in panels b and d are mean±s.d. (***Po0.001 by t-test) of three independent experiments.
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acetylation and H3K4 trimethylation and reduced H3K27
trimethylation and recruitment of EZH2, the histone methyl-
transferase for H3K27 trimethylation (Fig. 5j). Altogether, our
data indicate that Sp1 is responsible for the recruitment of
corepressor Hey1 to the USP11 promoter. Hey1 occupancy
leads to chromatin compaction and transcriptional repression
through a further recruitment of the histone modiﬁer PRC2
complex (Fig. 5i).
Notch induces Hey1 to downregulate USP11 and PML. Hey1 is
a downstream effector of Notch40,41. Accordingly, overexpression
of constitutively active Notch (Notch intracellular domain,
referred as NIC) in U87 and U251 cells downregulated USP11
and PML expression (Fig. 6a,b). Conversely, inactivation of Notch
by treatment of U87 and U251 cells with a g-secretase inhibitor
N-[N-(3,5-diﬂuorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl
ester (DAPT) increased USP11 and PML expression.
Furthermore, depletion of Notch1 by two independent siRNAs
also increased USP11 and PML expression (Fig. 6c). We also
observed that NIC or Hey1 overexpression in U87 and U251 cells
elevated PML ubiquitination (Fig. 6d), whereas DAPT inhibited
PML ubiquitination (Fig. 6e). Importantly, the NIC-induced PML
ubiquitination was abrogated by Hey1 depletion or USP11
overexpression (Fig. 6f). Finally, the NIC-induced PML
downregulation was reversed by proteasome inhibitor MG132
(Fig. 6g). These results establish a link between USP11 and
Notch and uncover a Notch/Hey1-induced PML degradation
pathway in GBM.
To determine whether the Notch/Hey1-dependent PML
degradation pathway exists in GICs, we utilized two primary
GBM patient-derived initiating cells, GBM9 and GBM004.
Overexpression of NIC in each GIC reduced USP11 and PML
(Fig. 6h), whereas g-secretase inhibitor or Notch1 siRNA
increased USP11 and PML (Fig. 6i,j). Thus, the Notch/Hey1/
USP11/PML pathway is manifested in GICs.
Notch/Hey1/USP11/PML axis promotes aggressive GBM
behaviours. Next, we evaluated the impact of Notch-induced
PML degradation pathway on GBM malignancy. For this pur-
pose, we established a set of stable cell lines derived from U251
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(Fig. 7a). Consistent with the proliferation effect of Notch on
GBM, DAPT signiﬁcantly reduced the proliferation of parental
U251 cells (Fig. 7b). Importantly, this effect was completely
blocked by Hey1 overexpression, USP11 depletion or PML
depletion. Similar ﬁndings were observed with another GBM cell
line, U87 (Supplementary Fig. 5a,b). Conversely, activation of this
PML degradation pathway by Hey1 overexpression, USP11
depletion or PML depletion in U87 and U251 cells enhanced the
proliferation and soft agar colony formation activities and the
effects of Hey1 overexpression or USP11 depletion were blocked by
PML-IV overexpression (Fig. 7c,d and Supplementary Fig. 5c,d).
These data support a role of Notch/Hey1-induced PML degrada-
tion pathway in GBM proliferation and transformation.
To demonstrate the role of Notch/Hey1-induced PML
degradation in brain tumour growth in vivo, we intracranially
injected U87 derivatives into nude mice. Mice injected with cells
expressing Hey1, USP11 shRNA or PML shRNA exhibited larger
brain tumours and shorter survival compared with those injected
with control cells (Fig. 7e). Furthermore, PML-IV overexpression
suppressed both Hey1-driven and USP11 shRNA-driven tumour
growth and prolonged survival (Fig. 7f,g). Our ﬁndings uncover a
key role of Notch/Hey1-induced PML degradation pathway in
brain tumour growth in vivo.
Notch/Hey1/USP11/PML axis potentiates GIC characteristics.
We next investigated the impacts of the Notch/Hey1-induced
PML degradation pathway on the biology of GICs. First, we tested
the self-renewal capability of GICs by sphere formation assay. As
expected, DAPT treatment of GBM9 cells reduced neurosphere
number and size. Importantly, Hey1 overexpression, USP11
depletion or PML depletion each rescued this effect of DAPT
(Fig. 8a). Similar results were observed with another GIC,
GBM004 (Supplementary Fig. 6a). We further showed that NIC
or Hey1 overexpression in GBM9 and GBM004 cells potentiated
self-renewal activity and these effects were abolished by USP11 or
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PML-I overexpression (Fig. 8b and Supplementary Fig. 6b). Of
note, PML-I was used in this case because it elicited a stronger
effect than PML-IV on suppressing neurosphere formation
(Supplementary Fig. 6c). In the reciprocal experiment, depletion
of Hey1 in GBM9 and GBM004 cells diminished the number and
size of neurospheres, which were reversed by PML depletion
(Fig. 8c and Supplementary Fig. 6d). These data provide
substantial evidence for the role of Notch/Hey1-induced
PML degradation pathway in promoting the self-renewal
capability of GICs.
Notch signaling is known to confer chemoresistance of GICs42.
Accordingly, DAPT sensitized GBM9 cells to temozolomide
(TMZ), a standard cytotoxic agent for treating GBM22. The
chemosensitizing effect of DAPT was abrogated by Hey1
overexpression, USP11 depletion or PML depletion (Fig. 8d). In
the reciprocal experiment, Hey1 silencing sensitized GBM9 cells
to TMZ, which was reversed by PML depletion (Fig. 8e). These
ﬁndings support the idea that Hey1-induced USP11 and PML
downregulation mediates the chemoresistant effect of Notch.
Next, we determined the role of Notch-induced PML
degradation in the tumour-forming ability of GICs by intracra-
nially injecting a small number of tumour cells to the nude mice.
Mice injected with the NIC-expressing GBM9 cells formed larger
brain tumours and survived shorter than mice injected with
GBM9 cells carrying control vector. This effect of NIC was
suppressed by co-expression of USP11 or PML-I (Fig. 8f).
Conversely, Hey1 shRNA signiﬁcantly suppressed the tumour-
forming ability of GBM9 cells and this effect was reversed by
PML depletion (Fig. 8g). Our data strongly support a role for the
Notch-induced PML degradation pathway in promoting the
tumour-forming ability of GICs.
PML is a major effector of Notch/Hey1/USP11 axis in GBM. To
corroborate that the effects of Notch/Hey1/USP11 axis on GBM
and GICs are dependent on PML ubiquitination/degradation, we
sought to generate a USP11-resistant mutant of PML. By
analysing a panel of PML deletion mutants, we found that
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residues 327–344 of PML was the minimal region required for
USP11 interaction (Fig. 9a,b). In line with this ﬁnding, ubiquiti-
nation of the PMLd327-344 mutant was no longer regulated by
USP11, NIC or Hey1, which was in sharp contrast to the wild-
type PML (Fig. 9c,d). Consequently, NIC- or Hey1-induced
downregulation and USP11-induced upregulation of PML were
completely abolished by this deletion (Fig. 9e–g). These data
identiﬁed PMLd327-344 as a mutant resistant to USP11-induced
deubiquitination.
Next, we tested the functional consequences of Hey1 over-
expression or USP11 depletion in cells stably expressing wild-type
PML or USP11-resistant PML. Remarkably, while Hey1 over-
expression or USP11 depletion efﬁciently blocked the expression
and anti-proliferation/migration/invasion effects of wild-type
PML in U251 cells, they failed to alter the expression and
functions of PMLd327-344 mutant (Fig. 10a,b). Similarly, NIC
overexpression, Hey1 overexpression or USP11 knockdown
drastically potentiated the self-renewal capability of GBM9 cells
stably expressing wild-type PML, but they exerted only minor
effects in cells expressing PMLd327-344 (Fig. 10c,d). These data
indicate that PML is a major effector of the Notch/Hey1/USP11
axis in regulating the malignancy of GBM and GICs.
Discussion
Our study provides the ﬁrst explanation of the molecular
mechanism of PML deubiquitination. We demonstrated that
USP11 deubiquitinates and stabilizes PML. The biological
signiﬁcance of this deubiquitination event is highlighted by the
ﬁnding of USP11 downregulation in glioma, especially in grade
IV GBM. Furthermore, this USP11 downregulation correlates
with PML downregulation. At a functional level, the USP11/PML
axis elicits inhibitory effects on multiple malignant characteristics
of GBM, including proliferation, migration and invasion. Our
study therefore uncovers the tumour suppressive effect of USP11-
dependent PML stabilization.
We further showed that USP11 is transcriptionally repressed
by the Notch effector Hey1. Notch signalling is aberrantly
activated in GBM and orchestrates the malignant traits of GBM
and GICs, but current knowledge regarding the downstream
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Figure 7 | Notch/Hey1-induced PML degradation pathway promotes GBM malignant phenotypes. (a) Western blot analysis of PML and USP11
expression levels in U251 derivatives. These stable lines were used in experiments shown in panels b–d. (b) Proliferation assay of U251 derivatives treated
with or without 10mM DAPT. (c) Proliferation assay of U251 derivatives as indicated. (d) Soft agar colony formation assay of U251 derivatives.
Representative images are shown on the left and quantitative data are on the right. Data in panels b–d are mean±s.d. (***Po0.001 by t-test of three
independent experiments). (e–g) Kaplan–Meier survival curves of mice implanted with U87 cells stably expressing indicated constructs (upper panels),
n¼ 6 mice for each indicated cell line. The P values were determined by log-rank test. Representative light micrographs of brain tumours formed at
indicated days after implantation are shown on the bottom panels. Brain tumours are marked by arrows. Scale bars, 2mm. The expression levels of USP11
and PML in the U87 derivatives are shown in Supplementary Fig. 5a.
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players of Notch in GBM remains limited43. Our discovery of a
link of USP11-dependent PML stabilization to the Notch/Hey1
axis highlights the signiﬁcant contribution of this pathway to
GBM malignancy. Indeed, using gain-of-function and loss-of-
function approaches and the expression of a USP11-resistant
PML mutant, we provide preclinical evidence showing that this
PML degradation pathway is a part of the Notch programme to
potentiate GBM proliferation, transformation and tumour
growth in vivo, as well as GIC self-renewal, chemoresistance
and tumour-forming capacities. Clinically, Hey1 overexpression,
indicative of activated Notch signalling, correlates with USP11
and PML downregulation in GBM patients, suggesting the
existence of this pathway and its aberrant activation in GBM.
Thus, our study provides a molecular mechanism for PML
downregulation in GBM and reveals a relevance of this PML
regulatory pathway to GBM pathogenesis (Fig. 10e).
The impact of the Notch/Hey1/USP11/PML pathway may
extend beyond GBM and GICs. In mouse forebrain development,
inactivation of Notch signalling compromises NPC maintenance,
leading to precocious neuronal differentiation43,44. Loss of PML,
however, suppresses the differentiation of radial glial cells, a type
of NPC, to committed progenitor cells19. The opposite effects of
PML and Notch on NPC fate decision are consistent with the
negative regulation of PML by Notch identiﬁed in this study.
Thus, it is tempting to propose that the Notch-induced PML
degradation pathway similarly acts on NPCs to affect their
maintenance and differentiation. Notably, USP11, one
component of this pathway, is preferentially expressed in the
forebrain (Supplementary Fig. 3a), implying its role in the
development of this brain region.
Although PML plays an inhibitory role in the maintenance of
NPCs and GICs, a beneﬁcial effect has been observed in
HSCs16,45. Given the complexity of stem/progenitor biology
and the pleiotropic functions of PML, it is conceivable that PML
could elicit such context-dependent effects. In line with this
notion, a recent study reveals an unexpected, pro-survival role of
PML in certain cellular settings45, opposing the well-established
pro-apoptotic function of PML. Given the highly heterogenous
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Figure 8 | Notch/Heyl-induced PML degradation pathway promotes GIC characteristic. (a) Neurosphere-forming abilities of GBM9 cells stably
expressing indicated constructs. (b) Neurosphere-forming abilities of GBM9 cells stably expressing indicated constructs. (c) Neurosphere-forming
abilities of GBM9 cells stably expressing indicated constructs. For panels (a–c), representative images of GIC neurospheres and their diameters
(represented as mean±s.d. of three independent experiments, 30 neurospheres per group per experiment) are indicated on the bottom. Scale bars,
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nature of GBM, future studies are needed to determine the
functions of the Notch/Hey1/USP11/PML axis in different GBM
subtypes. Notably, in addition to the cell intrinsic programme and
environmental milieu, the functional complexity of PML can also
be ascribed to the expression of different PML isoforms4,6.
Although our study indicates that most PML isoforms are
stabilized by USP11, they do not exert completely equivalent
impacts on GBM pathogenesis. For instance, PML-IV displays
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stronger suppressive effects than PML-I on GBM cell
proliferation, migration and invasion, but weaker effects on
GIC self-renewal. It is possible that different PML isoforms
interact with distinct partners, thus resulting in context-
dependent biological functions.
We have elucidated the mechanism by which Hey1 represses
USP11 promoter activity (Fig. 5i). Hey1 is recruited to USP11
promoter via interacting with Sp1, which binds GC-rich
sequences embedded in the CpG island of the USP11 promoter
(Supplementary Fig. 7a). Sp1 binding is known to protect DNA
from de novo methylation46,47. Consistently, the CpG island in
the USP11 promoter was hypomethylated in GBM cell line U87
and most GBM patient samples were analysed (Supplementary
Fig. 7b,c). Since CpG island methylation interferes with PRC2–
chromatin interaction48–52, the hypomethylated USP11 promoter
allows PRC2 recruitment by Hey1. The PRC2 component EZH2
catalyses H3K27 trimethylation, leading to chromatin comp-
action and transcriptional repression. Thus, Hey1 functions as a
transcriptional corepressor in USP11 transcription regulation and
a complex crosstalk among transcriptional factors, histone
modiﬁers and DNA methylation is involved in Hey1-mediated
repression of USP11.
In summary, our study identiﬁes a PML degradation pathway,
in which the Notch effector Hey1 represses PML-speciﬁc DUB
USP11 to potentiate PML ubiquitination and degradation. This
pathway is manifested in glioma, hyperactivated in GBM and
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contributes to the malignant characteristics of GBM and GICs.
Blockage of this pathway might be a therapeutic strategy for
treating the aggressive GBM.
Methods
Cell culture and transfection. HeLa, 293T, 293FT, H4, T98G, U87 and U251 cells
were obtained from the American Type Culture Collection and PML-null MEF
cells were obtained form Hsiu-Ming Shih. HeLa, 293T, 293FT, H4, T98G and
PML-null MEF cells were cultured in DMEM containing 10% FCS. U87 and U251
cells were cultured in MEM containing 10% FCS. GBM9 and GBM004 cells were
derived from pathologically diagnosed human GBM specimens under the approval
by The Ohio State University Institutional Review Board and informed consent was
obtained from these subjects. GICs were isolated using a method as described53. In
brief, tumours were dissociated using TrypLE Express (Invitrogen) and cultured in
Neurobasal medium (Invitrogen) with B27 (Invitrogen), human recombinant
leukaemia inhibitory factor (10 ngml 1; Chemicon International), basic ﬁbroblast
growth factor (50 ngml 1; PeproTech), epidermal growth factor (50 ngml 1;
Millipore), penicillin G (100 units ml 1), streptomycin (100 unitsml 1) and
L-glutamine (2mM; Invitrogen). The cells were validated for the expression of
CD133, and the characteristics of self-renewal, ability to form tumours in low
numbers and multilineage differentiation. GICs were grown as tumour spheres in
Neurobasal medium supplemented with B27, 2mM L-glutamine, 100 unitsml 1
penicillin G, 100 units ml 1 streptomycin, 20 ngml 1 epidermal growth factor
and 20 ngml 1 basic ﬁbroblast growth factor. Transfection was performed with
Lipofectamine 2000 Reagent (Invitrogen).
Antibodies and reagents. Antibodies used in this study and the validation
information are listed in Supplementary Table 1. DAPT was from Enzo. Cyclo-
heximide, TMZ and As2O3 were purchased from Sigma. MG132 was obtained from
Calbiochem.
Immunoﬂuorescent staining and high-throughput image analysis. Cells were
ﬁxed and permeabilized with ice-cold methanol for 20min and blocked with PBS
buffer supplemented with 10% goat serum and 1% BSA for 1 h. Cells were incu-
bated with primary antibody (Supplementary Table 1) at 4 C for overnight and
then with ﬂuorescein isothiocyanate-conjugated secondary antibody together with
1 gml 1 40,6-diamidino-2-phenylindole (DAPI) for 1 h. For high-throughput
quantifying the number and ﬂuorescent intensity of PML-NBs, cells were examined
by a Cellomics Arrayscan HT ﬂuorescence microscope with a  20 objective lens
(Thermo Scientiﬁc). Images were acquired by a Cellomics Spot Detector Bioap-
plication program and analysed by a Cellomics vHCS:View software. DAPI signal
was used for object selection. To correct plate-to-plate variation, the raw data were
normalized with positive control (KLHL20 shRNA) and negative control (luci-
ferase shRNA), which were included in each plate. Scores derived from two
independent experiments in which each shRNA was performed in triplicate were
averaged and plotted using the mean score of luciferase shRNA as 1.
For quantifying PML-NBs in cells expressing various constructs, cells were
examined by an epiﬂuorescent microscope (1 71; Olympus) equipped with a
camera (F-View II; Olympus) and controller software (analysis LS Research;
Olympus). The number of PML-NBs per cell was quantiﬁed by ImageJ software
using the function of Analyze Particles.
Plasmid constructs. Plasmids encoding myc-KLHL20, HA-ubiquitin, His-ubi-
quitin, myc-Cul3, myc-Roc1, HA-PML-I, HA-PML-IV, Flag-PML-I, Flag-PML-IV
and Flag-PML-I-3KR were described previously15,54. The construct for NIC55 was
obtained from Ming-Zong Lai. Complementary DNAs for wild-type USP11 and
C275/283S mutant were obtained from Winston CY Yu and then subcloned to
pRK5myc, pCMV and pVL1393myc. The resistant USP11 construct was generated
by site-directed mutagenesis. Hey1 cDNA was ampliﬁed by reverse transcriptase–
PCR and subcloned to pRK5F and pBybe-myc. Various PML and USP11 deletion
mutants were generated by PCR or ligation-mediated PCR. To clone USP11
promoter, a DNA fragment corresponding to nucleotides from  1,285 to þ 354
of the human USP11 gene was ampliﬁed from the genomic DNA of U87 cells and
inserted to pGL3-based vector. Promoter mutant constructs were generated by site-
directed mutagenesis. All constructs were veriﬁed by DNA sequencing.
RNA interference and lentivirus transduction. Lentivirus-based shRNA con-
structs were obtained from National RNAi Core Facility, Taiwan. The siRNAs to
Sp1, Hey1 and Notch1 were obtained from Dharmacon. The target sequences of
various shRNAs and siRNAs are listed in Supplementary Table 2. Lentivirus
generation and transduction were described previously15.
Real-time reverse transcriptase–PCR analysis. Quantitative real-time PCR
analysis was performed using the Power SYBR Green PCR Master kit (Applied
Biosystems). The sequences of various PCR primers are listed in Supplementary
Table 2. Ampliﬁcation was performed on Roche LightCycler 480 system.
Methylation-speciﬁc PCR and bisulphite sequencing. Bisulphite modiﬁcation of
genomic DNA was performed using the EZ DNA Methylation Kit (Zymo
Research). For MS–PCR, primers used for the methylated and unmethylated
USP11 promoter are listed in Supplementary Table 2. Genomic DNA from U87
cells treated in vitro by Sss1 methyltransferase (New England Biolabs) was used as a
positive control, and normal human blood DNA was used as a negative control.
For bisulphite sequencing, two pairs of primers used for amplifying USP11 pro-
moter CpG island are listed in Supplementary Table 2. The PCR products were
cloned and individual clone was sequenced and evaluated using the BIQ Analyzer
software.
Protein analysis. Cell extraction was performed with RIPA lysis buffer containing
50mM Tris (pH 8.0), 0.15M NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS,
1mM phenylmethyl sulphonyl ﬂuoride, 1 mgml 1 aprotinin and 1 mgml 1 leu-
peptin. In experiments shown in Supplementary Fig. 2c,e, 5 mM N-ethylmaleimide
(NEM) was added to the lysis buffer. Immunoprecipitation using cell lysates
containing equal amounts of proteins was performed as described previously56. For
in vitro pull-down analysis, Flag-PML-I was puriﬁed from baculovirus by anti-Flag
agarose beads and eluted by Flag-peptide. Recombinant myc-USP11 was separately
puriﬁed from baculovirus using c-myc AD agarose beads (Santa Cruz). The beads
were incubated with puriﬁed Flag-PML-I for 1 h in binding buffer containing
20mM Tris (pH 7.5), 150mM NaCl, 1% NP-40, 0.1% SDS and 1% sodium
deoxycholate and bound proteins were analysed by western blot. Full western blot
images are shown in Supplementary Figs 8–13.
In vitro deubiquitination assay. PML was ﬁrst ubiquitinated in vitro essentially as
described previously15. In brief, the puriﬁed Roc1–Cul3–KLHL20 complex bound
on glutathione-sepharose beads was incubated with 200 ng of Flag-PML-I
recombinant protein at 37 C for 1.5 h in 20ml reaction mixture containing 50mM
Tris (pH 7.5), 1 mM ubiquitin aldehyde, 20mM MG132, 5mM MgCl2, 2mM ATP,
2mM NaF, 1mM dithiothreitol, 10mg ubiquitin, 10mM creatine phosphate,
500 ng creatine kinase, 40 ng yeast E1 enzyme and 500 ng E2 enzyme (UbcH5a).
The reaction products were inactivated by heating for 15min at 70 C, and then
incubated with baculovirally puriﬁed USP11 or its mutant in 40 ml deubiquitination
reaction buffer containing 100mM HEPES (pH 7.4), 500mM NaCl, 100mM
MgCl2, 100mM dithiothreitol and 10mM ATP at 37 C for 2 h. Reaction products
were analysed by western blot.
In vivo deubiquitination. Cells transfected with various constructs together with
HA-ubiquitin and Flag-PML were treated with 1 mM MG132 for 16 h and then
lysed with RIPA lysis buffer supplemented with 1 mM MG132. Lysates were used
for immunoprecipitation with anti-Flag antibody, followed by western blot with
anti-HA antibody. Alternatively, cells expressing control or USP11 shRNA were
transfected with His-ubiquitin and treated with 1 mM MG132. Cells were lysed by
buffer A (6M guanidine-HCl, 0.1M Na2HPO4/NaH2PO4 (pH 8.0) and 10mM
imidazole), and lysates were incubated with Ni-NTA agarose for 2 h at 4 C. The
beads were washed twice with buffer A/TI (1 vol buffer A: 3 vol buffer TI (25mM
Tris–HCl, pH 6.8 and 20mM imidazole)), and ﬁve times with buffer TI, and then
analysed by western blot. In all experiments, equal expression of HA-ubiquitin or
His-ubiquitin was veriﬁed by western blot analysis.
Apoptosis assay. GBM9 derivatives (2 105) were pretreated with 25 mM DAPT
or dimethylsulphoxide for 24 h and then with 25 mM TMZ for 48 h. Neurospheres
were dissociated with Accutase (Millipore) and apoptotic cells were assayed by
Annexin V kit (BD Pharmingen).
Cell assays. Cell proliferation was assayed using Cell Proliferation ELISA BrdU kit
(Roche). In brief, 1 104 cells were seeded on plate and 5-bromo-20-deoxyuridine
was added to culture medium at 18 h after plating. 5-bromo-20-deoxyuridine
labelling was proceeded for 1 h before cell harvest. Transwell migration and
invasion assays were performed essentially as described56. In brief, 2 104 cells
were seeded on Transwell plate and incubated in culture medium for 6 h (for
migration assay) or 18 h (for invasion assay). To distinguish migration/invasion
effect from proliferation effect, the same number of cells was seeded on a regular
culture plate. At the end of incubation, cells that had migrated onto the lower
membrane surface of the Transwell plate were ﬁxed with 4% formaldehyde, stained
with DAPI and counted. The cell number was normalized with that appearing in
the regular plate. For proliferation, migration and invasion assays, all data are
presented as relative activities with the untreated control group as 1.
Luciferase and ChIP assays. For luciferase assay, cells were cotransfected with
pGL3-based reporter construct and pCMV-renilla. Forty hours after transfection,
luciferase activity in cell lysate was assayed by the Dual Luciferase Reporter Assay
System (Promega). The relative promoter activity was expressed as the fold change
in ﬁreﬂy luciferease activity after normalization to the renilla luciferase activity.
ChIP assays were performed as described previously15. In brief, cells were ﬁxed
with 1% formaldehyde and processed for ChIP with various antibodies or normal
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mouse antiserum IgG (as a control). Enrichment of promoter binding levels was
analysed by quantitative PCR, normalized by a negative control (located at a distal
region of Hey1 promoter without E box- and Sp1-binding site), and expressed as
fold increase over the control. The PCR primers for ChIP analysis are listed in
Supplementary Table 2.
Tissue specimens and IHC analysis. Freshly isolated human GBM specimens
and benign tumour tissues (for MS–PCR) were obtained from Tri-service General
Hospital, Taiwan. In addition, a human brain tumour microarray (for IHC) was
obtained from Biomax Inc. Studies involving these tissues were approved by the
Institutional Review Boards at Tri-Service General Hospital and Academia Sinica
and informed consent was obtained from all subjects. For IHC analysis, antigen
retrieval was performed by heat denaturation of parafﬁn sections with 10mM
sodium citrate buffer (pH 6.0) for 30min. Endogenous peroxidase activity was
blocked by incubation in 3% H2O2 at room temperature for 20min and nonspeciﬁc
binding was blocked by Avidin/Biotin Blocking kit (Invitrogen). The slides were
incubated with anti-Hey1 (1:100), anti-PML (1:100) or anti-USP11 (1:100) anti-
body in PBS containing 10% goat serum at room temperature for 2 h. The bound
antibody was detected by biotinylated anti-mouse/rabbit IgG followed by perox-
idase-labelled streptavidin and visualized with 3,30-diaminobenzidine in chromo-
gen solution (Dako LASB kit). The sections were counterstained with
haematoxylin. The IHC staining was scored as negative/weak positive (score 0),
moderate positive (score 1þ ) and strong positive (score 2þ ) based on percentage
of cells staining positive and staining intensity. Samples with score 2þ are deﬁned
as high expression and those with score 1þ and score 0 are deﬁned as low
expression.
Soft agar colony formation and neurosphere formation assays. For assaying
colony formation in soft agar, 2 104 U87 or U251 cell derivatives were resus-
pended in 0.3% top agar. Colony formed after 4 weeks were stained by crystal violet
and the colony number was quantiﬁed by ImageJ software. For assaying neuro-
sphere formation, GICs infected with lentivirus expressing various cDNAs and/or
shRNAs were plated on 96-well plates at a density of 1 cell per well and cultured in
GIC culture medium with or without DAPT. After 10 days, the percentage of wells
containing neurospheres was quantiﬁed and neurospheres were imaged by a light
microscope (1 71; Olympus) equipped with a camera (F-View II; Olympus). All
data were normalized with the untreated control group.
Intracranial tumour assays. All mice experiments were conducted with approval
from the Experimental Animal Committee, Academia Sinica, and followed
guidelines of ethical regulations. For intracranial injection, 7- to 9-week-old, male
BALB/c nude mice were anaesthetized and placed into stereotactic frame. The burr
hole in the skull was drilled 1mm anterior and 1.8mm lateral to the bregma. Cells
were resuspended in PBS and injected at a depth of 3.0mm from the surface of the
brain. For pathological analysis, three animals per group were used. At the
appropriate days after injection, the mice were deeply anaesthetized and brains
were ﬁxed by intracardiac perfusion with 4% paraformaldehyde followed by a 12 h
of immersion ﬁxation. Brains were sectioned and parafﬁn-embedded sections were
processed for haematoxylin and eosin staining.
Bioinformatics. Human USP11 tissue expression data were retrieved from the
Genevestigator database (https://www.genevestigator.com/gv/) using the Anatomy
function. Microarray data derived from Human 133_2 (Human Genome 47k
array) Array Platform were downloaded and output as a Heatmap-Tree with the
Log2 display pattern. Transcriptional factor-binding site prediction was performed
with the PROMO 3.0 program (http://www.alggen.lsi.upc.es/cgi-bin/promo_v3/
promo/promoinit.cgi?dirDB=TF_8.3). A region from 3,000 bp upstream to
3,000 bp downstream of the transcriptional start site of USP11 gene was queried
and all human transcription factors and all sites were selected for analysis.
Microarray and clinical data of glioma patients were obtained from the
REMBRANDT database (http://www.rembrandt.nci.nih.gov/). Gene expression
values derived from the Affymetrix U133 plus 2.0 Array Platform for USP11 were
downloaded for all glioma samples and normal samples through the Advanced
Search function and via the caINTEGRATOR homepage. ChIP-seq data were
retrieved from the UCSC Genome Browser (http://www.genome.ucsc.edu/)
assembled on March 2006. The locations of transcription factors bound to human
USP11 50-regulatory region were displayed by the Encode Transcription factor
ChIP-seq function.
Statistical analysis. The two-tailed, Student’s t-test was used to compare between
two groups and expressed as P-values. *Po0.05, **Po0.01 and ***Po0.001. The
Fisher’s exact test was used to compare the dichotomous variables. The Kaplan–
Meier estimation and the log-rank test were used to compare the survival differ-
ence. All data were derived from independent experiments and the cells were not
pooled across experiments.
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In Fig. 4e of this Article, images of western blots were inadvertently duplicated from the corresponding images in Fig. 4d during the
production process. The correct version of this ﬁgure appears below as Fig. 1.
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